Oxcarbazepine Tablet, Film Coated
Product Images NDC 70518-2370

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 70518-2370). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm7 (Oxcarbazepine 300mg 70518 2370 01)

Oxcarbazepine is a prescription drug (RX ONLY) supplied in a HD2 quantity with NDC# 70518-2370-01. The manufacturer is Breckenridge located in Boca Raton, FL, and the repackager is RemedyRepack Inc. from Indiana, PA. It is important to keep this medication out of reach of children. It is advised to read the package insert before use and store the medication at a temperature between 20-26°C (63-77°F), with excursion permitted to 15-30°C (59-86°F) [See USP]. The expiration date and LOT# are not readable.*

FDA Label Image

Remedy_label (Remedy Label)

Oxcarbazepine is a prescription medication that comes in a package of 100 HD2 tablets. The National Drug Code (NDC) number for this medication is 70518-2370-00 and it is manufactured by Breckenridge in Boca Raton, Florida. The lot number and expiration date are not provided. The medication should be kept out of reach of children and stored between 20-26°C (63-77°F) with permitted excursions to 15-30°C (59-86°F). The package insert should be consulted for directions on how to use the medication. This particular package has been repackaged by RemedyRepack Inc. in Indiana, PA.*

FDA Label Image

Chemical Structure (Oxcarbazepine 01)

FDA Label Image

Figure 1 (Oxcarbazepine 02)

The text displays statistical analysis related to the exit rate and log-rank test in a trial, with a graph indicating results over time. The trial includes a placebo.*

FDA Label Image

Figure 2 (Oxcarbazepine 03)

The text describes the seizure rate and the statistical analysis performed using the log-rank test. The p-value obtained from the test is 0.046, which indicates a significant difference between the groups being compared. The graph shows the number of days from the first dose to the first seizure, and the treatment groups being compared are Oxcarbazepine and placebo.*

FDA Label Image

Figure 3 (Oxcarbazepine 04)

This is a survival analysis report with the test result of log-rank test showing a significant p-value of 0.0001. A chart is also displayed showing the time it takes to exit in days for a treatment group categorized as either "HIGH" or "LOW".*

FDA Label Image

Figure 4 (Oxcarbazepine 05)

This is a survival analysis of two treatment groups (high and low) evaluating their exit rate over time. The log-rank test resulted in a p-value of 0.0001 indicating a statistically significant difference in exit rate between the two groups. The time to exit is measured in days over a period of 130 days. The data presented in the text is primarily a graph with the x-axis representing time to exit (in days) and the y-axis representing the percentage of participants exiting the study. The treatment group with a high exit rate is marked on the graph.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.